Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Multicenter, Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-3001 in Participants with Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease

NCT06622668 is registered in ClinicalTrials.gov with Intellia Therapeutics as lead sponsor.

NCT NCT06622668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06622668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Multicenter, Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-3001 in Participants with Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease
Lead sponsor
Intellia Therapeutics
Phase
Phase 1/2
Overall status
Withdrawn
Start date
November 20, 2024
Completion date
January 9, 2025
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aatd, alpha-1 antitrypsin deficiency, alpha-1 antitrypsin deficiency-associated lung disease, lung disease, pulmonary disease